# Tapering off Inhaled Corticosteroids in Asthma patients after Reduction of Allergens

Submission date	Recruitment status No longer recruiting Overall study status	<ul><li>Prospectively registered</li></ul>		
19/12/2005		☐ Protocol		
Registration date		Statistical analysis plan		
19/12/2005	Completed	[X] Results		
<b>Last Edited</b> 25/08/2009	Condition category Respiratory	[] Individual participant data		

## Plain English summary of protocol

Not provided at time of registration

# **Contact information**

## Type(s)

Scientific

#### Contact name

Prof C.P. Schayck, van

#### Contact details

University Maastricht
Care and Public Health Research Institute - CAPHRI
Department of General Practice
P.O. Box 616
Maastricht
Netherlands
6200 MD
+31 (0)43 3882446
onno.vanschayck@hag.unimaas.nl

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

**NTR370** 

# Study information

#### Scientific Title

#### Acronym

**TICARA** 

#### Study objectives

Allergen avoidance allows tapering off inhaled corticosteroids (ICS) in house dust mite allergic asthma patients

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Received from local medical ethics committee

#### Study design

Multicentre randomised double blind placebo controlled parallel group trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

## Study setting(s)

Other

#### Study type(s)

Other

## Participant information sheet

#### Health condition(s) or problem(s) studied

Asthma, Allergy

#### Interventions

All patients have been trained to use a self-management plan to adjust the dose of inhaled corticosteroids to symptoms and peak expiratory flow value.

After a run-in period of 3 months the intervention period with placebo controlled allergen avoidance started.

The participants in the intervention group received house dust mite impermeable covers for mattress, pillow and bedding.

The control group received placebo, house dust mite permeable, covers.

#### Intervention Type

Other

#### **Phase**

**Not Specified** 

#### Primary outcome measure

Use of inhaled corticosteroids

#### Secondary outcome measures

- 1. Asthma control
- 2. Symptoms (dyspnoea, wheezing, coughing)
- 3. Peak flow parameters (morning peak flow, peak flow variability)

#### Overall study start date

01/01/1999

#### Completion date

01/12/2004

# **Eligibility**

#### Key inclusion criteria

- 1. Age 16-60 years
- 2. Treatment for asthma by the GP
- 3. Use of inhaled corticosteroids
- 4. Allergy for house dust mite allergens

#### Participant type(s)

Patient

#### Age group

Adult

#### Sex

Both

# Target number of participants

150

#### Key exclusion criteria

- 1. Serious diseases other than asthma with a low survival rate
- 2. Other diseases, which influence bronchial symptoms and/or lung function
- 3. Exacerbation within one month before the start of the study
- 4. The use of oral steroids or inhaled cromoglycates
- 5. Use of house dust mite impermeable mattress/bedding covers
- 6. Allergy to cats or dogs while keeping these pets

#### Date of first enrolment

01/01/1999

#### Date of final enrolment

01/12/2004

# Locations

#### Countries of recruitment

Netherlands

Study participating centre University Maastricht Maastricht Netherlands 6200 MD

# Sponsor information

#### Organisation

Care and Public Health Research Institute (CAPHRI), University Maastricht (Netherlands)

#### Sponsor details

P.O. Box 616
Maastricht
Netherlands
6200 MD
+31 (0)43 3882446
e.habets@caphri.unimaas.nl

#### Sponsor type

Research organisation

#### ROR

https://ror.org/02jz4aj89

# Funder(s)

#### Funder type

Research organisation

#### **Funder Name**

Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

#### Alternative Name(s)

Netherlands Organisation for Health Research and Development

## **Funding Body Type**

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

#### Location

Netherlands

#### Funder Name

Netherlands Asthma Foundation (Netherlands)

#### Funder Name

Boehringer Ingelheim BV (Netherlands)

#### Funder Name

AstraZeneca BV (Netherlands)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2006		Yes	No